Welcome to our dedicated page for Mannkind news (Ticker: MNKD), a resource for investors and traders seeking the latest updates and insights on Mannkind stock.
MannKind Corporation (MNKD) specializes in innovative inhaled therapies for diabetes and respiratory diseases, notably through its FDA-approved Afrezza® inhaled insulin. This page aggregates official announcements, clinical trial updates, and strategic partnership news critical for understanding the company's trajectory.
Investors and researchers will find curated press releases covering financial results, regulatory milestones, and technology licensing agreements. The collection emphasizes developments in MannKind's core platforms: the Technosphere® drug delivery system and iSPERSE™ formulation technology.
Content includes updates on pulmonary arterial hypertension treatments, diabetes management solutions, and global expansion initiatives. All materials maintain factual accuracy without speculative analysis, adhering to financial disclosure standards.
Bookmark this page for streamlined access to MNKD's latest business developments and scientific advancements. Verify time-sensitive details directly through company filings or official communications.
MannKind Corporation (Nasdaq: MNKD) announced the advancement of clofazimine inhalation suspension (MNKD-101) to an adaptive Phase 2/3 study, paving the way for a potential treatment for nontuberculous mycobacterial (NTM) lung disease. Published findings highlight the product's tolerability and toxicokinetics, suggesting it could reduce systemic toxicity associated with oral treatments. An estimated 86,000-180,000 individuals in the U.S. suffer from NTM lung disease, which is on the rise. FDA has designated MNKD-101 as both an orphan lung and qualified infectious disease product (QIDP), indicating its potential significance in addressing this growing health concern.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will present at the 2023 Annual J.P. Morgan Healthcare Conference on January 12, 2023, at 11:15 AM PST in San Francisco, California. Interested parties can listen to the webcast on the company's website, which will also be archived for replay. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, emphasizing rapid medicine delivery through their signature inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced promising results from the Afrezza with Basal Combination (ABC) Study, presented on November 10, 2022, at the Annual Diabetes Technology Meeting. Technosphere Insulin (TI) demonstrated a faster peak effect, occurring 30 minutes sooner, and significantly reduced postprandial glucose excursions at 60 minutes compared to subcutaneous insulins, with values of 57.9 mg/dL versus 101.4 mg/dL. No severe hypoglycemia was reported, highlighting TI's potential as a pump-sparing option for diabetes patients.
MannKind Corporation (MNKD) reported 3Q 2022 total revenues of $32.8 million, marking a 48% increase compared to 3Q 2021. Afrezza net revenue rose 11% to $10.8 million, with total revenues for the nine-month period reaching $63.7 million. The company experienced a 67% revenue growth in its Endocrine Business Unit, driven by Afrezza and V-Go demand. However, the net loss for 3Q 2022 was $14.4 million, reflecting increased SG&A and interest expenses. Gross profit for Afrezza improved to 81% margin compared to 61%
MannKind Corporation (Nasdaq: MNKD) is set to release its 2022 third quarter financial results and year-to-date performance on November 8, 2022, at 9:00 AM ET.
CEO Michael Castagna and CFO Steven Binder will discuss the results during a conference call, accessible via the company's website. MannKind focuses on innovative therapies for endocrine and lung diseases, utilizing advanced inhalation technologies. For further details, visit their official site.
MannKind Corporation (Nasdaq: MNKD) announced that its CEO, Michael Castagna, PharmD, will participate in the Lytham Partners Fall 2022 Investor Conference on September 28-29, 2022. The company's webcast presentation will be available on September 28 at 9:00 am ET via its website. Additionally, management will hold virtual one-on-one meetings during the event. MannKind focuses on developing innovative therapeutic products for endocrine and orphan lung diseases, particularly utilizing advanced dry-powder formulations and inhalation devices.
MannKind Corporation (Nasdaq: MNKD) announced the successful completion of a Phase 1 study on clofazimine inhalation suspension (MNKD-101) for treating nontuberculous mycobacterial (NTM) lung disease. The study indicated that the inhalation solution was well tolerated, with no serious adverse events or QT prolongation. The FDA has designated MNKD-101 as an orphan lung and qualified infectious disease product, addressing a high unmet medical need. MannKind plans discussions with the FDA regarding the findings and the ongoing clinical program.
MannKind Corporation (Nasdaq: MNKD) announced CEO Michael Castagna will present at the H.C. Wainwright 24th Annual Global Investment Conference on September 13, 2022, at 12:00 PM ET in New York. The company focuses on developing innovative therapeutic products for endocrine and orphan lung diseases. Interested parties can access the live webcast and replay for 14 days via the company’s website. MannKind aims to improve the lives of patients using their advanced inhalation devices and formulations for conditions like diabetes and pulmonary arterial hypertension.
MannKind Corporation (Nasdaq: MNKD) reported a total revenue of $18.9 million for Q2 2022, a 28% increase year-over-year, driven by Afrezza net revenue of $10.6 million. The FDA approved Tyvaso DPI, contributing to revenue recognition. However, collaborations revenue decreased by $7.4 million compared to Q2 2021. The net loss decreased to $29.0 million, or $0.11 per share, from $35.5 million, aided by improved gross profit margins. Expenses rose due to heightened promotional efforts for Afrezza and V-Go.
MannKind Corporation (Nasdaq: MNKD) will announce its 2022 second-quarter financial results on August 9, 2022, at 5:00 PM Eastern Time. CEO Michael Castagna and CFO Steven Binder will lead a conference call to discuss these results and the company's updates. MannKind focuses on developing innovative therapies, particularly for conditions like diabetes and pulmonary arterial hypertension, leveraging its specialized dry-powder delivery technology. Investors can access the live call through the company’s website for detailed insights on performance and strategy.
FAQ
What is the current stock price of Mannkind (MNKD)?
What is the market cap of Mannkind (MNKD)?
